Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | XDH | P47989 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30632104 | 1.00 | GAA (0.50) | GAAKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL7347988 | 0.93 | GAA (0.50) | GAAKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL23704095 | 0.87 | GAA (0.54) | GAAKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL31024702 | 0.85 | CA12 (0.50) | GAAKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL25342477 | 0.85 | CA12 (0.50) | GAAKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL25641842 | 0.84 | HTT (0.56) | GAAKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL24515512 | 0.83 | CA12 (0.40) | GAAKDM4EALDH1A1SMN1; SMN2CA12 | |
| SCHEMBL24515876 | 0.83 | CA12 (0.40) | GAAKDM4ESMN1; SMN2CA12CA1 | |
| SCHEMBL24436889 | 0.83 | CA12 (0.48) | GAAKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL1300753 | 0.81 | GAA (0.49) | GAAKDM4EALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260069559-A1 | COMBINATIONS OF RXFP1 MODULATORS AND SGLT2 INHIBITORS | ASTRAZENECA AB (SE) | 2026-03-12 | — | — | US | disclosed |
| US-20260069558-A1 | RXFP1 MODULATORS FOR TREATING RESISTANT HYPERTENSION OR HEART FAILURE WITH PULMONARY HYPERTENSION | ASTRAZENECA AB (SE) | 2026-03-12 | — | — | US | disclosed |
| CN-119630638-A | Solid forms of RXFP1 modulators | 阿斯利康(瑞典)有限公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-119486724-A | RXFP1 modulators for the treatment of refractory hypertension or heart failure combined with pulmonary hypertension | 阿斯利康(瑞典)有限公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-119325376-A | Combination of RXFP1 modulator and SGLT2 inhibitor | 阿斯利康(瑞典)有限公司 | 2025-01-17 | — | — | CN | disclosed |
| WO-2023237511-A1 | RXFP1 MODULATORS FOR TREATING RESISTANT HYPERTENSION OR HEART FAILURE WITH PULMONARY HYPERTENSION | ASTRAZENECA AB (SE) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023237511-A1 | RXFP1 MODULATORS FOR TREATING RESISTANT HYPERTENSION OR HEART FAILURE WITH PULMONARY HYPERTENSION | ASTRAZENECA AB (SE) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023237510-A1 | SOLID FORMS OF RXFP1 MODULATORS | ASTRAZENECA AB (SE) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023237510-A1 | SOLID FORMS OF RXFP1 MODULATORS | ASTRAZENECA AB (SE) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023237512-A1 | COMBINATIONS OF RXFP1 MODULATORS AND SGLT2 INHIBITORS | ASTRAZENECA AB (SE) | 2023-12-14 | — | — | WO | disclosed |
| US-20230348363-A1 | COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-11-02 | — | — | US | disclosed |
| US-20230348363-A1 | COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-11-02 | — | — | US | disclosed |
| EP-4259605-A1 | 4-(2-FLUORO-4-METHOXY-5-3-(((1-METHYLCYCLOBUTYL)METHYL)CARBAMOYL)BICYCLO[2.2.1]HEPTAN-2-YL)CARBAMOYL)PHENOXY)-1-METHYLCYCLOHEXANE-1-CARBOXYLIC ACID DERIVATIVES AND SIMILAR COMPOUNDS AS RXFP1 MODULATORS FOR THE TREATMENT OF HEART FAILURE | Astrazeneca AB (SE) | 2023-10-18 | — | — | EP | disclosed |
| CN-116547270-A | 4- (2-fluoro-4-methoxy-5-3- (((1-methylcyclobutyl) methyl) carbamoyl) bicyclo [2.2.1] hept-2-yl) carbamoyl) phenoxy) -1-methylcyclohexane-1-carboxylic acid derivatives and similar compounds as RXFP1 modulators for the treatment of heart failure | 阿斯利康(瑞典)有限公司 | 2023-08-04 | — | — | CN | disclosed |
| US-11667602-B2 | Compounds and their use | ASTRAZENECA AB (SE) | 2023-06-06 | — | — | US | disclosed |
| US-11667602-B2 | Compounds and their use | ASTRAZENECA AB (SE) | 2023-06-06 | — | — | US | disclosed |
| US-11667602-B2 | Compounds and their use | ASTRAZENECA AB (SE) | 2023-06-06 | — | — | US | disclosed |
| US-20230078576-A1 | COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-03-16 | — | — | US | disclosed |
| WO-2022122773-A1 | 4-(2-FLUORO-4-METHOXY-5-3-(((1-METHYLCYCLOBUTYL)METHYL)CARBAMOYL)BICYCLO[2.2.1]HEPTAN-2-YL)CARBAMOYL)PHENOXY)-1-METHYLCYCLOHEXANE-1-CARBOXYLIC ACID DERIVATIVES AND SIMILAR COMPOUNDS AS RXFP1 MODULATORS FOR THE TREATMENT OF HEART FAILURE | ASTRAZENECA AB (SE) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022122773-A1 | 4-(2-FLUORO-4-METHOXY-5-3-(((1-METHYLCYCLOBUTYL)METHYL)CARBAMOYL)BICYCLO[2.2.1]HEPTAN-2-YL)CARBAMOYL)PHENOXY)-1-METHYLCYCLOHEXANE-1-CARBOXYLIC ACID DERIVATIVES AND SIMILAR COMPOUNDS AS RXFP1 MODULATORS FOR THE TREATMENT OF HEART FAILURE | ASTRAZENECA AB (SE) | 2022-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260069559-A1 | COMBINATIONS OF RXFP1 MODULATORS AND SGLT2 INHIBITORS | RXFP1, RXFP2, RXFP4 | GAA 4746/4885KDM4E 3555/4885ALDH1A1 2557/4885 |
| US-11667602-B2 | Compounds and their use | RXFP1, RXFP3, RXFP2 | GAA 3044/4885KDM4E 2832/4885ALDH1A1 1531/4885 |
| US-20230348363-A1 | COMPOUNDS AND THEIR USE | RXFP1, RXFP3, RXFP2 | GAA 3044/4885KDM4E 2832/4885ALDH1A1 1531/4885 |
| US-20260069558-A1 | RXFP1 MODULATORS FOR TREATING RESISTANT HYPERTENSION OR HEART FAILURE WITH PULMONARY HYPERTENSION | RXFP1, RXFP3, RXFP2 | GAA 4869/4885KDM4E 4092/4885ALDH1A1 2913/4885 |
| US-20230078576-A1 | COMPOUNDS AND THEIR USE | RXFP1, RXFP3, RXFP2 | GAA 3044/4885KDM4E 2832/4885ALDH1A1 1531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.